{"name":"Gerresheimer AG","slug":"gerresheimer","ticker":"GXI","exchange":"XETRA","domain":"gerresheimer.com","description":"Gerresheimer AG, together with its subsidiaries, provides medicine packaging, drug delivery devices, and solutions in Germany and internationally. The company operates through three divisions: Plastics & Devices, Primary Packaging Glass, and Advanced Technologies. It offers prefillable syringes, plastic and glass packaging solutions, vials, glass cartridges and ampoules, bottles and containers, and containers, bottles, caps, closures, applicators, and accessories; development, industrialization and contract manufacturing of drug delivery programs; project and quality management; and drug delivery devices, including inhalers, injection/auto injectors, and pen injectors. The company also provides diagnostic and medical devices comprising point-of-care tests, laboratory disposables, chemical and technical bottles, diagnostic and polymer vials, dropper bottles, PET bottles, and medical products comprising lancing devices, infusion sets, and disposable systems. In addition, it offers cosmet","hq":"Düsseldorf, Germany","founded":1994,"employees":"13535","ceo":"Dietmar Siemssen","sector":"Pharma Packaging & Drug Delivery Devices","stockPrice":25.14,"stockChange":-1.34,"stockChangePercent":-5.06,"marketCap":"$1.0B","metrics":{"revenue":2628813160.9815555,"revenueGrowth":12.5,"grossMargin":26.9,"rdSpend":0,"netIncome":27278037.405,"cash":170410056.2110944,"dividendYield":15,"peRatio":37,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2028-06-01","label":"EpiPen patent cliff ($1.5B at risk)","drug":"EpiPen","type":"patent_expiry","sentiment":"negative"},{"date":"2029-06-01","label":"Albuterol patent cliff ($1.2B at risk)","drug":"Albuterol","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-28","type":"earnings","headline":"Gerresheimer AG Reports Strong Q4 2023 Results","summary":"Gerresheimer AG reported strong Q4 2023 results, with revenue growth driven by increased demand for packaging solutions.","drugName":"","sentiment":"positive"},{"date":"2023-09-01","type":"deal","headline":"Gerresheimer AG Acquires Majority Stake in US-Based Packaging Company","summary":"Gerresheimer AG acquired a majority stake in a US-based packaging company to expand its presence in the North American market.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxQakswUnZwY21uOTRhZmpHYWk1ZkRpX2tOUEh4NmxwYTFGZWp1VEFRQVpOV2ZDWVJiUFNTUm9yZjZ2WmV1ZlpJdjJQa01XSF9qR3JyWjBsMDZrd0tyR29Kbl9yZERRbXBfT2ZoZkZBUXFKb2VlMGxnUkV2cDdEZW1CRGFneklFNGV2aldjU1Y0Z1NDTUZpbEd3N2RFcTNEZlVrRFRTVkJfd3RtUQ?oc=5","date":"2026-03-18","type":"earnings","source":"Meyka","summary":"GXI.DE Gerresheimer AG XETRA pre-market €19.34 18 Mar 2026: earnings set to guide - Meyka","headline":"GXI.DE Gerresheimer AG XETRA pre-market €19.34 18 Mar 2026: earnings set to guide","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-02-10","type":"pipeline","source":"simplywall.st","summary":"Investors Don't See Light At End Of Gerresheimer AG's (ETR:GXI) Tunnel - simplywall.st","headline":"Investors Don't See Light At End Of Gerresheimer AG's (ETR:GXI) Tunnel","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikAJBVV95cUxQYS1mREpmbWFRN3pjaGtJQ1ZCRW5JNkcyTkxPYTN0WUxrTXVHckZPRGp0WF9UVU5JSkJ6R0J5ek9IRlFoZml5Xzd4cktpUkNKbW9xVFhxYU41RlVwWmdFYW5vb3p6MHg1Z055TUJJaXc2Nm5DSlVtSWREZmNDaEo1dVNZT3ZiY2xEdDlDbHhGX3dqa1ltVXlJempHWHpLeUtyalF1em1MdXdEcnI3UDlNaEJmaC1oa203MUNQeUNlcGtFRGd4QkxqWFhlNUxnMi1fWTI5S3hmM0xBRnViT2xOY0oyMkdnZ012bnVhdFBKU0hXWTVQZ0xvNjNlLWlVWG54M0ZRX2pSUWVWLUtNS1VEQw?oc=5","date":"2026-02-10","type":"pipeline","source":"TradingView","summary":"Gerresheimer AG reschedules publication of annual and consolidated financial statements for 2025 and initiates sale of Centor Inc. - TradingView","headline":"Gerresheimer AG reschedules publication of annual and consolidated financial statements for 2025 and initiates sale of C","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-01-15","type":"pipeline","source":"simplywall.st","summary":"In the wake of Gerresheimer AG's (ETR:GXI) latest €57m market cap drop, institutional owners may be forced to take severe actions - simplywall.st","headline":"In the wake of Gerresheimer AG's (ETR:GXI) latest €57m market cap drop, institutional owners may be forced to take sever","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-05-30","type":"pipeline","source":"simplywall.st","summary":"Shareholders May Be Wary Of Increasing Gerresheimer AG's (ETR:GXI) CEO Compensation Package - simplywall.st","headline":"Shareholders May Be Wary Of Increasing Gerresheimer AG's (ETR:GXI) CEO Compensation Package","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-05-14","type":"pipeline","source":"simplywall.st","summary":"Is There Now An Opportunity In Gerresheimer AG (ETR:GXI)? - simplywall.st","headline":"Is There Now An Opportunity In Gerresheimer AG (ETR:GXI)?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwAFBVV95cUxOb2tFUWRYZEtjQUVMSVRQWDV3QmtYWjYzRDJINFFuT1NDd196eUF6aUQ5ZzJnakZaVmwzbzIxMFpibjNvYV9iRGsxR01DSE9lc1pzdEhGQ1MtWE1Bc0ZGYXpVck4xbEpWVkZudThCN05uWGg1OU5OVGhSMDZGRWdFN0M4ZTMyVWlzcTVNZ1JQRnU2ZG5ESkQ1eFhrN3RVS1FqZFNMMU13d19hTTRUdjZ4TEJyemtmZElqWlVLTVVTUzg?oc=5","date":"2024-09-26","type":"pipeline","source":"Stevanato Group","summary":"Stevanato Group, Gerresheimer and SCHOTT Pharma, Announce Strategic Industry “Alliance for RTU” - Stevanato Group","headline":"Stevanato Group, Gerresheimer and SCHOTT Pharma, Announce Strategic Industry “Alliance for RTU”","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiVEFVX3lxTE9RR3BEYmF3NUZFbjRXTEE4NTJXYlNlWnlHemtHMVE4dk9Ib1BySmRWWDFLMklybld4ejh0STg4V0FfWGdtaWx5ZHJpY0Nhc0RJM1lJSQ?oc=5","date":"2017-06-12","type":"pipeline","source":"Yahoo Finance Australia","summary":"Gerresheimer AG (GXI.DE) stock price, news, quote and history - Yahoo Finance Australia","headline":"Gerresheimer AG (GXI.DE) stock price, news, quote and history","sentiment":"neutral"}],"patents":[{"drugName":"EpiPen","drugSlug":"epinephrine","patentNumber":"","type":"Patent Cliff","expiryDate":"2028-06-01","territory":"US","annualRevenue":1500000000},{"drugName":"Albuterol","drugSlug":"albuterol","patentNumber":"","type":"Patent Cliff","expiryDate":"2029-06-01","territory":"US","annualRevenue":1200000000}],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Amcor Limited","West Pharmaceutical Services Inc.","Becton, Dickinson and Company"],"therapeuticFocus":["Injectables","Ophthalmics","Respiratory"],"financials":{"source":"yahoo_finance","revenue":2378391357.0429,"revenuePeriod":"2024-11-30","revenueHistory":[{"period":"2024-11-30","value":2378391357.0429},{"period":"2023-11-30","value":2325334114.0098004},{"period":"2022-11-30","value":2122773366.1842003},{"period":"2021-11-30","value":1750008178.9701002}],"grossProfit":710005841.6895001,"grossProfitHistory":[{"period":"2024-11-30","value":710005841.6895001},{"period":"2023-11-30","value":697796729.5302},{"period":"2022-11-30","value":638799065.9316001},{"period":"2021-11-30","value":521404206.0246}],"rdSpend":26144859.834000003,"rdSpendHistory":[{"period":"2024-11-30","value":26144859.834000003},{"period":"2023-11-30","value":18839953.2861},{"period":"2022-11-30","value":25255841.141700003},{"period":"2021-11-30","value":11646028.0467}],"sgaSpend":399233645.17920005,"operatingIncome":272891355.3585,"operatingIncomeHistory":[{"period":"2024-11-30","value":272891355.3585},{"period":"2023-11-30","value":268071261.89670002},{"period":"2022-11-30","value":226299065.60160002},{"period":"2021-11-30","value":221247663.72840002}],"netIncome":128177570.19600001,"netIncomeHistory":[{"period":"2024-11-30","value":128177570.19600001},{"period":"2023-11-30","value":135661215.0618},{"period":"2022-11-30","value":112289719.716},{"period":"2021-11-30","value":97883177.64840001}],"eps":3.18,"epsHistory":[{"period":"2024-11-30","value":3.18},{"period":"2023-11-30","value":3.48},{"period":"2022-11-30","value":3.06},{"period":"2021-11-30","value":2.67}],"cash":217731308.58540002,"cashHistory":[{"period":"2024-11-30","value":217731308.58540002},{"period":"2023-11-30","value":142919392.63770002},{"period":"2022-11-30","value":131762850.57270001},{"period":"2021-11-30","value":133237149.63930002}],"totalAssets":4449957947.4852,"totalLiabilities":2651896030.1589003,"totalDebt":1497893692.7871,"equity":1765843459.3566,"operatingCashflow":280761682.46760005,"operatingCashflowHistory":[{"period":"2024-11-30","value":280761682.46760005},{"period":"2023-11-30","value":343851635.78910005},{"period":"2022-11-30","value":259276869.36630002},{"period":"2021-11-30","value":247752336.6468}],"capex":-432063084.45780003,"capexHistory":[{"period":"2024-11-30","value":-432063084.45780003},{"period":"2023-11-30","value":-383220794.6991},{"period":"2022-11-30","value":-282125000.2257},{"period":"2021-11-30","value":-237880841.31180003}],"freeCashflow":-151301401.9902,"dividendsPaid":null,"buybacks":null,"employees":13535,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":123021028.1358,"ebit":61161215.00220001,"ebitda":139494158.99010003,"period":"2025-05-31","revenue":701699766.9165001,"epsBasic":0.49,"netIncome":19886682.2589,"rdExpense":3689252.3394000004,"epsDiluted":0.49,"grossProfit":184380841.26900002,"operatingIncome":59191588.8324},{"sga":120523364.58240001,"ebit":20108644.8759,"ebitda":98599299.14430001,"period":"2025-02-28","revenue":607539720.1122,"epsBasic":-0.52,"netIncome":-21043224.3159,"rdExpense":7146028.0431,"epsDiluted":-0.52,"grossProfit":148072430.025,"operatingIncome":17661214.967400003},{"sga":70283878.5609,"ebit":75988317.8178,"ebitda":136753504.78230003,"period":"2024-11-30","revenue":664571262.2139001,"epsBasic":null,"netIncome":43272196.2963,"rdExpense":8054906.5485000005,"epsDiluted":null,"grossProfit":212242990.82400003,"operatingIncome":114122663.64270002},{"sga":111075934.6683,"ebit":59123831.82300001,"ebitda":118021028.13180001,"period":"2024-08-31","revenue":582376168.6902001,"epsBasic":0.79,"netIncome":31786214.978700005,"rdExpense":5567757.013800001,"epsDiluted":0.79,"grossProfit":172706775.8391,"operatingIncome":56522196.3069}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":25.14,"previousClose":26.48,"fiftyTwoWeekHigh":66.5,"fiftyTwoWeekLow":14.83,"fiftyTwoWeekRange":"14.83 - 66.5","fiftyDayAverage":21,"twoHundredDayAverage":27.98,"beta":0.45,"enterpriseValue":3627620488.883405,"forwardPE":9.4,"priceToBook":0.62,"priceToSales":0.39,"enterpriseToRevenue":1.38,"enterpriseToEbitda":8.07,"pegRatio":0,"ebitda":449749981.6682112,"ebitdaMargin":17.1,"freeCashflow":-662026542.5856961,"operatingCashflow":296281532.9473056,"totalDebt":2699262805.8977284,"debtToEquity":161.8,"currentRatio":0.98,"returnOnAssets":2.3,"returnOnEquity":1.8,"analystRating":"3.2 - Hold","recommendationKey":"hold","numberOfAnalysts":11,"targetMeanPrice":24.04,"targetHighPrice":46,"targetLowPrice":12.5,"dividendRate":0.04,"payoutRatio":0.06,"fiveYearAvgDividendYield":1.36,"exDividendDate":1749168000,"insiderHeldPercent":11,"institutionHeldPercent":92.9,"sharesOutstanding":34540000,"floatShares":32048630,"sharesShort":0,"shortRatio":0,"shortPercentOfFloat":0,"epsTrailing":0.68,"epsForward":2.67,"revenuePerShare":65.15,"bookValue":40.59,"officers":[{"age":44,"name":"Ms. Katja  Schnitzler","title":"Global Senior VP of People & Organization and Member of Supervisory Board"},{"age":63,"name":"Mr. Uwe Ferdinand Röehrhoff","title":"Chairman of the Management Board & CEO"},{"age":54,"name":"Mr. Wolf Uwe Lehmann","title":"CFO & Member of the Management Board"},{"age":53,"name":"Mr. Achim  Schalk","title":"Member of the Management Board"},{"age":null,"name":"Mr. Guido  Pickert","title":"Head of Investor Relations"},{"age":null,"name":"Ueli  Utzinger","title":"Group Senior Director Marketing & Communication"},{"age":64,"name":"Mr. Hans-Norbert  Topp","title":"Head of Moulded Glass Business Unit"},{"age":39,"name":"Ms. Carolin  Nadilo","title":"Corporate Director of Investor Relations"}],"industry":"Medical Instruments & Supplies","irWebsite":"http://www.gerresheimer.com/en/investor-relations.html","website":"https://www.gerresheimer.com","phone":"49 211 61 81 00"}}